five-year follow-up of olutasidenib for idh1-mutated r/r aml
Published 2 months ago • 86 plays • Length 1:31Download video MP4
Download video MP3
Similar videos
-
3:10
results of phase ii trial of olutasidenib in patients with r/r midh1 aml
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml
-
1:13
5-year follow-up of patients with cll treated in first-line with ibrutinib plus venetoclax
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
4:06
what is leukapheresis?
-
4:54
imugene reports promising results in phase 1b trial for azer-cel in dlbcl
-
45:21
builders #12 w/ tim lu (co-founder & ceo) & kanya rajangam (cmo/cdo) @ senti bio | bios
-
1:51
idh1/2 inhibitors for upfront aml therapy and transfusion independence
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:52
aml19 update: improvement in os in patients with npm1-mutated aml treated with flag-ida-go
-
2:53
a 5-year follow-up of ruxolitinib plus azacitidine in mds/mpn overlap syndromes and cmml
-
1:51
10-year follow-up of the lnh03-6b trial: outcomes of older patients with dlbcl treated with r-chop
-
0:44
predictors of poor response to azacitidine, venetoclax, and magrolimab in tp53-mutated aml
-
3:58
five-year follow up of the uk cll forum ibrutinib data
-
2:55
post-transplant pd1 blockade plus autologous lymphocytes in r/r hl
-
2:14
addressing the high rate of disease relapse following allosct in patients with aml
-
3:29
opb-11077 for newly diagnosed and r/r aml: phase ib update
-
1:02
a phase ii single-arm study of obinutuzumab plus ibrutinib as frontline treatment for fl and mzl
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
1:34
single-center study evaluating the outcomes of patients with aml who relapsed after allosct